Inverse Agonist

What is an Inverse Agonist?

An inverse agonist is a molecule that binds to a receptor and produces an effect opposite to that of an agonist. This occurs because many receptors have constitutive (baseline) activity even without a ligand bound. While an agonist increases receptor activity above baseline and an antagonist simply blocks agonist binding, an inverse agonist actively reduces receptor activity below its resting level.

How Inverse Agonists Work

The mechanism of inverse agonism involves receptor conformational states:

1. Constitutive activity: Some receptors spontaneously adopt active conformations, producing baseline signaling
2. Agonist binding: Stabilizes active conformations, increasing signaling above baseline
3. Inverse agonist binding: Stabilizes inactive conformations, reducing signaling below baseline
4. Neutral antagonist binding: Blocks both agonists and inverse agonists without affecting baseline activity

This distinction has important therapeutic implications for receptors with significant constitutive activity.

Inverse Agonists in Peptide Research

Several peptides demonstrate inverse agonist properties:

• Agouti-related peptide (AgRP): Acts as an inverse agonist at melanocortin MC3 and MC4 receptors, opposing the effects of alpha-MSH and stimulating appetite
• Certain somatostatin analogs: Can function as inverse agonists at specific somatostatin receptor subtypes

Understanding inverse agonism helps explain why some peptides produce effects stronger than simple receptor blockade.

Clinical Significance

Inverse agonists are particularly valuable when:

• Treating conditions with overactive receptors: Reducing pathologically elevated baseline signaling
• Targeting constitutively active mutant receptors: Some diseases involve mutations that increase baseline receptor activity
• Achieving greater efficacy: When neutral antagonists provide insufficient therapeutic effect

Related Concepts

• Constitutive activity: Spontaneous receptor signaling without ligand
• Neutral antagonist: Blocks agonists without affecting baseline activity
• Efficacy spectrum: Range from full agonist to inverse agonist